Skip to main content
Premium Trial:

Request an Annual Quote

Rodney Turner, Biolog, Cellomics, Cisbio, Cell & Molecular Technologies, GE Healthcare, MDS Sciex, PerkinElmer



Kalypsys has hired Rodney Turner to lead worldwide sales efforts for the company's automated drug discovery systems, the firm said last week. He will oversee the sales and marketing efforts for the full range of Kalypsys automated systems to academic and government institutions and pharmaceutical customers in the United States and, for the first time, Europe and Asia.

Turner comes to Kalypsys from RTK Group, a life science strategic consultancy based in San Francisco, where he was a partner and co-founder. Previously, he was vice president of business development for Fluidigm. Before that, Turner was with Evotec AG of Hamburg, Germany, where he managed sales and marketing for drug discovery services.



Following is a list of notable new cell-based assay products launched at the Society for Biomolecular Screening conference, held last week in Geneva, Switzerland.

Biolog introduced its first Phenotype MicroArray for mammalian cells.

The Phenotype MicroArray cellular array technology has already been applied for use with bacteria, yeast, and filamentous fungi. The mammalian cell line capability will allow additional use of Phenotype MicroArrays in drug discovery, functional genomics, and cellular toxicology, Biolog said.

The arrays have already been optimized for use in a wide variety of cell lines, including HepG2 and C3A liver cell lines; CRF-CEM and HL60 leukemia cell lines; Colo 205 colon cancer cell line; A549 non-small cell lung cancer cell line; and non-immortalized mammalian cell lines.

Cellomics launched the Tube Formation BioApplication for conducting high-content angiogenesis assays on all versions of its ArrayScan and KineticScan HCS readers.

The tube formation BioApplication is an image-analysis algorithm that allows scientists to quantitatively analyze angiogenic tube formation in vitro by measuring the morphology of endothelial cells and tubes, Cellomics said.

Cisbio introduced three new cyclic AMP assays that use its HTRF technology, the cAMP dynamic 2, cAMP femto 2, and cAMP HiRange assays.

The assays incorporate d2, a small-molecule organic dye developed by Cisbio to optimize assay performance and stability when measuring GPCR activation, Cisbio said. The upgraded cAMP dynamic 2 and cAMP femto 2 assays, along with the new cAMP HiRange assay, take into account the variability of customers' biological material and cover a wide range of cAMP concentration, Cisbio said. The cAMP dynamic 2 assay is the kit of reference, suitable for most applications; cAMP femto 2 is the most sensitive of the three; and cAMP HiRange is used when the target has high level of expression, Cisbio said.

Cell & Molecular Technologies, a subsidiary of Sentigen Biosciences, launched the Tango GPCR assay platform.

According to CMT, the assay platform comprises a panel of 54 GPCR targets. Key features of the luciferase-based chemiluminescent assay platform include up to 1,700-fold signal-to-background rations, high specificity, and broad applicability to novel targets, including orphan receptors.

GE Healthcare launched three new cell-based assay products: the Micronucleus software application for the IN Cell Analyzer 1000 and 3000; the Optical Z-sectioning module for the IN Cell Analyzer 1000; and the Adenoviral Vector Gene Delivery System.

The Micronucleus software application allows genotoxicity screens for potential drug compounds. It identifies genotoxicity by finding breaks in DNA, and, along with the IN Cell Analyzer 3000, can analyze a 96-well plate within 10 minutes, GE Healthcare said.

The Optical Z-sectioning module extends the image quality obtained in cellular assays to tissue section imaging on the IN Cell Analyzer 1000 by removing out-of-focus light from above and below the focal plane, GE said.

The adenoviral vector gene delivery system is a range of ready-to-use recombinant adenoviral preparations, each of which contains the gene encoding a protein target fused to EGFP or emerald FP, or a response element controlling the expression of nitroreductase.

MDS Sciex introduced the CellKey System for label-free cellular analysis.

The CellKey is based on a concept of cellular dielectric spectroscopy, which allows measurements of endogenous cell surface receptor activation in live cells and generates data that enables identification of the receptor coupling mechanism of unknown receptors, including GPCRs. The instrument conducts cellular assays without fluorescent labels or radio-labeled markers, thereby simplifying assay development, MDS Sciex said.

PerkinElmer launched the LumiLux luminescent µHTS cellular screening platform.

LumiLux enables luminescent cellular screening in 1,536-well format with significantly higher throughput than existing technologies, and features an integrated cell stirrer, PerkinElmer said. For more on the LumiLux launch, see related story in this issue, "PerkinElmer Eyes M&A, Deals …".

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.